A phase-I study of the safety, pharmacokinetics, and antiviral activity of combination didanosine and ribavirin in patients with HIV-1 disease. AIDS Clinical Trials Group 231 Protocol Team.

doi:10.1097/00042560-199611010-00005

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

A phase-I study of the safety, pharmacokinetics, and antiviral activity of combination didanosine and ribavirin in patients with HIV-1 disease. AIDS Clinical Trials Group 231 Protocol Team.

Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association - 1 Nov 1996

Japour A J, Lertora J J, Meehan P M, Erice A, Connor J D, Griffith B P, Clax P A, Holden-Wiltse J, Hussey S, Walesky M, Cooney E, Pollard R, Timpone J, McLaren C, Johanneson N, Wood K, Booth D, Bassiakos Y, Crumpacker C S

Abstract excerpt

A phase-I study was conducted to examine the safety, pharmacokinetics, and activity of combination 2',3'-dideoxyinosine (ddI) and ribavirin against human immunodeficiency virus type 1 (HIV-1)-positive individuals with CD4+ cell counts of < or = 500/microliter. Nineteen patients were enrolled into...

Topics

Adult
Anti-HIV Agents
Antiviral Agents
CD4 Lymphocyte Count
Didanosine
Drug Interactions
Drug Therapy, Combination
Female
Genetic Variation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Giant Cells

HIV Infections

HIV-1

Humans

Male

Middle Aged

RNA, Viral

Ribavirin

Viremia

Source

Open in PubMed

Identifiers

PMID: 8898668
DOI: 10.1097/00042560-199611010-00005

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 30 Aug 2026. Prepared record publication-8898668-2026-08-30.1. Manifest publication-graph-cohort-2026-08-30.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 30 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.